Merck & Co. Inc. on Wednesday projected first-quarter earnings above Wall Street expectations, but stuck to its earlier forecast that full-year 2005 earnings will decline up to 7% following the recall of its Vioxx arthritis drug.
*For more on this story,
read the full Reuters article.
